The market is starting to wake up to the opportunity. ARDS results due, oil sales ramping up, 3 other significant clinical trials pending...
The benchmark is GW Pharma who developed Epidiolex, a CBD drug treating 2 rare forms of epilepsy.
The drug was launched in 2019 and generated $296 million in sales in its first full year and recently reported $120 million of sales just in the first quarter of 2020. Their market capitalization is nearly $4 billion.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-963
-
-
- There are more pages in this discussion • 19,133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin